Inmode Ltd


Inmode Ltd

Health CareHealth Care Equipment & Services
  • Price (USD)113.67
  • Today's Change-2.36 / -2.03%
  • Shares traded653.60k
  • 1 Year change+246.87%
  • Beta--
Data delayed at least 15 minutes, as of Jul 30 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company’s products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.

  • Revenue in USD (TTM)287.75m
  • Net income in USD127.58m
  • Incorporated2008
  • Employees311.00
  • Location
    Inmode LtdTavor Building, Sha'ar Yokneam, Pob 533YOKNEAM 2069200IsraelISR
  • Phone+972 49097470
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Axonics Inc119.61m-62.80m3.10bn416.00--8.66--25.91-1.64-1.643.117.890.36121.075.66287,528.80-18.96---20.31--59.43---52.50--6.53-42.520.1855--707.06--31.30------
NuVasive, Inc.1.15bn1.85m3.26bn2.70k1,823.363.8822.232.830.03460.034622.3116.280.48081.015.78427,098.500.07731.550.09731.8172.3172.620.16072.572.301.820.51210.00-10.065.31-156.95--0.3312--
Integer Holdings Corp1.04bn67.68m3.29bn7.50k48.782.5722.,064.402.852.293.082.4726.4129.446.545.191.582.710.34970.00-14.686.05-15.30--2.89--
Owens & Minor, Inc.8.68bn166.57m3.45bn6.30k18.714.3813.320.39722.451.54131.5310.472.445.9512.371,378,416.004.69-1.107.90-1.8016.7612.651.92-0.39480.66095.190.5552---7.93-2.80489.98-2.9910.08-60.27
Merit Medical Systems, Inc.969.26m4.27m3.64bn5.99k916.563.7237.703.750.07080.070817.3517.460.572.626.45161,840.500.25101.360.2821.5242.2343.600.44042.171.157.400.2470.00-3.1112.20-280.57---1.41--
AtriCure Inc.212.58m-48.66m3.82bn750.00--9.75--17.95-1.13-1.134.938.580.34631.698.20283,441.30-7.93-8.44-8.61-9.3572.9072.67-22.89-17.004.48-10.170.1333---10.529.74-36.83---17.12--
Conmed Corp978.50m54.14m4.02bn3.40k79.77--31.824.101.731.7331.79--------287,794.40--1.60--1.7955.2954.665.532.75--2.40--96.80-9.703.70-66.75-20.78-2.810.00
ICU Medical Inc1.26bn93.77m4.25bn7.90k46.182.7923.533.374.344.3458.3371.760.70372.647.91159,549.805.
LivaNova PLC1.02bn-379.12m4.34bn4.00k--4.17--4.25-7.79-7.8020.9721.240.41712.335.55255,431.00-15.47-4.59-19.29-5.5365.3064.85-37.09-11.050.9711-0.67770.3892---13.83---120.85------
Premier Inc1.58bn212.30m4.37bn2.50k19.221.979.492.761.861.8615.1618.110.46925.563.85632,956.009.8617.3212.7721.3951.9468.0321.0133.540.778514.030.22090.006.735.23165.12--5.94--
Inmode Ltd287.75m127.58m4.43bn311.0038.7413.3834.6015.402.992.996.768.670.92672.5421.43925,241.2041.10--46.32--85.14--44.35--8.49--0.00--31.81--22.71------
Inari Medical Inc170.12m17.15m4.47bn456.00411.2620.88235.3226.260.21870.21873.554.311.161.597.40373,059.2011.66--12.95--91.17--10.08--10.0758.350.00--173.17--1,256.96------
Inspire Medical Systems Inc134.39m-57.17m4.87bn317.00--21.80--36.20-2.14-,930.60-26.04---28.16--84.8982.51-42.54-50.6212.84-34.490.10--40.6270.48-72.08--47.98--
Novanta Inc (USA)597.74m43.88m4.87bn2.20k111.9310.2258.858.141.231.2316.7413.460.70563.466.66271,699.505.186.446.097.6741.6342.067.347.961.877.700.29350.00-5.679.599.194.5613.64--
Nevro Corp363.19m-87.74m5.37bn843.00--14.64--14.80-2.56-2.5610.5710.560.58791.235.55430,831.60-14.20-12.91-18.90-15.3269.7369.17-24.16-17.962.65-2.350.4624---7.2339.0719.89--3.77--
Helen of Troy Limited2.22bn250.63m5.47bn1.77k22.754.5519.012.479.989.9888.7549.881.033.066.001,254,487.0011.599.5514.8011.7343.6542.2911.2910.480.902426.430.2983--22.928.5558.7921.3442.70--
Data as of Jul 30 2021. Currency figures normalised to Inmode Ltd's reporting currency: US Dollar USD

Institutional shareholders

19.29%Per cent of shares held by top holders
HolderShares% Held
Acadian Asset Management LLCas of 31 Mar 20211.58m4.14%
Van Berkom & Associates, Inc.as of 31 Mar 20211.06m2.79%
Menora Mivtachim Insurance Ltd.as of 31 Mar 20211.00m2.63%
William Blair Investment Management LLCas of 31 Mar 2021702.86k1.84%
Fidelity Management & Research Co. LLCas of 31 Mar 2021625.44k1.64%
Marshall Wace Asia Ltd.as of 31 Mar 2021536.41k1.41%
American Century Investment Management, Inc.as of 31 Mar 2021506.77k1.33%
Renaissance Technologies LLCas of 31 Mar 2021486.68k1.27%
Putnam Investment Management LLCas of 31 Mar 2021440.52k1.15%
Victory Capital Management, Inc. (Investment Management)as of 31 Mar 2021419.11k1.10%
More ▼
Data from 31 Mar 2021 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.